OMS
MCID: OTT002
MIFTS: 71

Otitis Media (OMS)

Categories: Ear diseases, Genetic diseases

Aliases & Classifications for Otitis Media

MalaCards integrated aliases for Otitis Media:

Name: Otitis Media 57 12 74 29 55 3 44 15 17 72
Otitis Media, Susceptibility to 57 29 6
Otitis Media, Chronic/recurrent 57 74
Come/rom 57 74
Oms 57 74
Otitis Media Susceptibility to 13
Infectious Otitis Media 72
Om 74

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32

Classifications:



External Ids:

Disease Ontology 12 DOID:10754
OMIM 57 166760
ICD9CM 35 382.9
MeSH 44 D010033
NCIt 50 C34885
SNOMED-CT 68 65363002
MedGen 42 C1833692
UMLS 72 C0029882 C2827407

Summaries for Otitis Media

CDC : 3 Ear infections can affect the ear canal or the middle ear. Acute otitis externa (AOE) is the scientific name for an infection of the ear canal, which is also called swimmer's ear. Middle ear infections are called Otitis Media, and there are two types of middle ear infections: Otitis Media with Effusion (OME) occurs when fluid builds up in the middle ear without pain, pus, fever, or other signs and symptoms of infection. Acute Otitis Media (AOM) occurs when fluid builds up in the middle ear and is often caused by bacteria, but can also be caused by viruses.

MalaCards based summary : Otitis Media, also known as otitis media, susceptibility to, is related to suppurative otitis media and haemophilus influenzae. An important gene associated with Otitis Media is A2ML1 (Alpha-2-Macroglobulin Like 1), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Halofantrine and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and brain, and related phenotypes are recurrent otitis media and hematopoietic system

Disease Ontology : 12 A otitis which involves inflammation of the middle ear.

UniProtKB/Swiss-Prot : 74 Otitis media: An inflammation of the middle ear resulting in earache, fever, hearing disturbance, and vertigo.

Wikipedia : 75 Otitis media is a group of inflammatory diseases of the middle ear. The two main types are acute otitis... more...

More information from OMIM: 166760

Related Diseases for Otitis Media

Diseases related to Otitis Media via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 837)
# Related Disease Score Top Affiliating Genes
1 suppurative otitis media 35.3 TLR4 TLR2 IL1B
2 haemophilus influenzae 32.5 TNF TLR2 IL1B CXCL8
3 rhinitis 31.4 RNASE3 IGHE CXCL8 CCL11
4 allergic rhinitis 31.3 RNASE3 IGHE CXCL8 CCL11
5 osteomyelitis 31.3 TNF IL6 IL1B CXCL8
6 laryngitis 31.2 TNF IL6 IL1B
7 sleep apnea 31.2 TNF IL6 IL1B CXCL8
8 mycobacterium abscessus 31.2 TNF TLR2 CXCL8
9 tonsillitis 31.1 TNF IL6 IL1B CXCL8 CD79A
10 septic arthritis 31.1 TLR4 TLR2 CXCL8
11 mycobacterium fortuitum 31.1 LACTB CXCL8
12 conjunctivitis 31.0 RNASE3 IL6 CXCL8 CCL11
13 common cold 31.0 RNASE3 MUC5AC CXCL8 CCL11
14 spinal cord injury 31.0 TNF IL6 CXCL8
15 bone inflammation disease 31.0 TNF IL6 IL1B CXCL8
16 tuberculous meningitis 30.9 TNF TLR2 CXCL8
17 arthritis 30.9 TNF IL6 IL1B CXCL8
18 mycobacterium chelonae 30.9 TLR2 CXCL8
19 bacterial meningitis 30.9 TNF TLR2 IL6 IL1B CXCL8
20 pertussis 30.9 TNF TLR4 IL6 IL1B
21 lymphadenitis 30.8 TNF TLR4 IL1B CXCL8
22 duodenal ulcer 30.8 TNF IL1B CXCL8
23 rheumatic fever 30.8 TNF MBL2 IL6
24 pulmonary tuberculosis 30.8 TNF TLR2 MBL2
25 aseptic meningitis 30.7 TNF IL1B CXCL8
26 appendicitis 30.7 TNF IL6 IL1B CXCL8
27 meningitis 30.7 TNF TLR2 MBL2 LACTB IL6 IL1B
28 peptic ulcer disease 30.7 TNF IL1B CXCL8
29 bacterial pneumonia 30.7 TLR4 LACTB IL6 CXCL8
30 cytomegalovirus infection 30.7 TNF IL6 IL1B CXCL8
31 bacterial sepsis 30.7 TNF TLR4 CXCL8
32 respiratory allergy 30.7 RNASE3 IGHE CCL11
33 chronic maxillary sinusitis 30.7 RNASE3 MUC5B MUC5AC
34 bronchiectasis 30.7 TLR2 MBL2 CXCL8
35 bronchitis 30.7 TNF RNASE3 LACTB CXCL8 CCL11
36 fasciitis 30.6 TNF IL6 CXCL8
37 pericarditis 30.6 TNF IL6 IL1B
38 hemorrhagic fever with renal syndrome 30.6 TNF IL6 CXCL8
39 hypereosinophilic syndrome 30.6 RNASE3 IGHE CCL11
40 meningoencephalitis 30.6 IL6 CD79A CD40LG
41 pulmonary edema 30.6 TNF IL1B CXCL8
42 listeriosis 30.5 TNF MBL2 IL6
43 acquired immunodeficiency syndrome 30.5 TNF IL6 IL1B
44 alveolar echinococcosis 30.5 TNF TLR4 TLR2
45 mycobacterium tuberculosis 1 30.5 TNF TLR4 TLR2 MBL2
46 purpura 30.5 TNF IL6 CD79A
47 bacterial infectious disease 30.4 TNF TLR4 TLR2 MBL2 IL6 IL1B
48 contact dermatitis 30.4 TNF IL6 IL1B CXCL8
49 monocytic leukemia 30.4 TNF IL6 IL1B CXCL8
50 infective endocarditis 30.4 TNF TLR2 IL6

Comorbidity relations with Otitis Media via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Cholesteatoma of Middle Ear Deficiency Anemia
Heart Disease Hypertension, Essential
Labyrinthitis Mastoiditis
Otitis Externa Pneumococcal Meningitis

Graphical network of the top 20 diseases related to Otitis Media:



Diseases related to Otitis Media

Symptoms & Phenotypes for Otitis Media

Human phenotypes related to Otitis Media:

32
# Description HPO Frequency HPO Source Accession
1 recurrent otitis media 32 HP:0000403

Symptoms via clinical synopsis from OMIM:

57
Head And Neck Ears:
otitis media

Clinical features from OMIM:

166760

MGI Mouse Phenotypes related to Otitis Media:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CCL11 CD40LG CD79A IL1B IL6 MBL2
2 homeostasis/metabolism MP:0005376 9.93 CD40LG CD79A FBXO11 IL1B IL6 MBL2
3 immune system MP:0005387 9.77 CCL11 CD40LG CD79A FBXO11 IL1B IL6
4 respiratory system MP:0005388 9.17 CCL11 IL6 MUC5B SFTPA1 TLR2 TLR4

Drugs & Therapeutics for Otitis Media

Drugs for Otitis Media (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 244)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Halofantrine Approved Phase 4 69756-53-2 37393
2
Sodium citrate Approved, Investigational Phase 4 68-04-2
3
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
4
Cefdinir Approved Phase 4 91832-40-5 6915944
5
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
7
Azithromycin Approved Phase 4 83905-01-5 447043 55185
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
9
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
10
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
11
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
12 Strawberry Approved Phase 4
13
Morphine Approved, Investigational Phase 4 57-27-2 5288826
14
Lumefantrine Approved Phase 4 82186-77-4 6437380
15
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
16
Artemether Approved Phase 4 71963-77-4 68911 119380
17
Artesunate Approved, Investigational Phase 4 88495-63-0 5464098 6917864
18
Montelukast Approved Phase 4 158966-92-8 5281040
19
Histamine Approved, Investigational Phase 4 51-45-6 774
20
Ofloxacin Approved Phase 4 82419-36-1 4583
21
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
22
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
23
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
24
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
25
Cetirizine Approved Phase 4 83881-51-0 2678
26
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
27
Ephedrine Approved Phase 4 299-42-3 9294
28
Phenylephrine Approved Phase 4 59-42-7 6041
29
Pseudoephedrine Approved Phase 4 90-82-4 7028
30
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
31
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
32
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
33
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
34
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
35
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
36
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
37
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
38
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
39
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
40
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
41
BCG vaccine Investigational Phase 4
42
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
43
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
44
Propyl Gallate Investigational Phase 4 121-79-9 4947
45 Analgesics, Non-Narcotic Phase 4
46 Anti-Inflammatory Agents, Non-Steroidal Phase 4
47 Antirheumatic Agents Phase 4
48 Cyclooxygenase Inhibitors Phase 4
49 Citrate Phase 4
50 Ketorolac Tromethamine Phase 4

Interventional clinical trials:

(show top 50) (show all 318)
# Name Status NCT ID Phase Drugs
1 The Influence of The Ear Popper on Serous Otitis Media and on the Accompanying Conductive Hearing Loss in Children Unknown status NCT00393159 Phase 4
2 Phase 4 Efficacy Study of Antimicrobials in the Treatment of Acute Otitis Media in Young Children Unknown status NCT00299455 Phase 4 amoxicillin-clavulanate;Placebo
3 Prospective, Randomized, Allocation-Concealed, Blinded Study Designed to Compare Ketorolac Sublingual and Fentanyl Intranasal in Pain Control for Bilateral Myringotomy and Tubes (BMT) Placement in Children Unknown status NCT02653742 Phase 4 Ketorolac;Fentanyl
4 Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Unknown status NCT00494624 Phase 4 prednisolone
5 A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children Completed NCT00189462 Phase 4 Montelukast
6 Amoxycillin Versus Placebo for Resolution of Otitis Media With Effusion and Prevention of Acute Otitis Media With Perforation in Aboriginal Infants: a Randomised Controlled Trial. Completed NCT00539149 Phase 4 Amoxycillin;Placebo equivalent to amoxycillin
7 A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media Completed NCT00644943 Phase 4 cefdinir (Omnicef);amoxicillin
8 A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media Completed NCT00645112 Phase 4 cefdinir (Omnicef);azithromycin
9 A Double-Blind, Randomized, Placebo-Controlled Study of Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age Completed NCT00593502 Phase 4 oseltamivir;placebo
10 A Randomised Controlled Trial of Pneumococcal Conjugate Vaccines Synflorix and Prevenar13 in Sequence or Alone in High-risk Indigenous Infants (PREV-IX_COMBO): Immunogenicity, Carriage and Otitis Media Outcomes Completed NCT01174849 Phase 4 Synflorix;Prevenar13;COMBO
11 Evaluation of the Effects of Enterogermina, 2 Billion Bacillus Clausii Spores, on the Intestinal Flora of Children Antibiotic Treated for Bacterial Upper Respiratory Tract Infections: Open, Pilot Study. Completed NCT00424905 Phase 4 Bacillus clausii
12 Role of Empiric Anti-reflux Therapy in Pediatric Otitis Media With Effusion - a Pilot Study Completed NCT01082029 Phase 4 Lansoprazole;Placebo
13 Efficacy of Antimicrobials in Young Children With Acute Otitis Media (AOM) Completed NCT00377260 Phase 4 amoxicillin-clavulanate;Placebo
14 Postoperative Analgesic and Behavioral Effects of Intranasal Fentanyl, Intravenous Morphine and Intramuscular Morphine in Pediatric Patients Undergoing Bilateral Myringotomy and Placement of Ventilating Tubes Completed NCT01244126 Phase 4 Intranasal fentanyl;morphine IM;IV morphine
15 Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®) Completed NCT00419380 Phase 4 dornase alfa (Pulmozyme®)
16 Comparison of the Immunogenicity of the 3+1 Schedule and the 2+1 Schedule of 7-valent Pneumococcal Conjugated Vaccine in Young Chinese Infants Completed NCT02040402 Phase 4
17 Clinical Trial for the Assessment of Delayed Antibiotic Treatment in the Non-complicated Acute Respiratory Tract Infections in Pediatric (Study DAP-Pediatrics) Completed NCT01800747 Phase 4
18 Does Vaccinating Health Hutterite Children Against Influenza Prevent Influenza in Other Hutterite Colony Members: A Randomized Cluster Trial Completed NCT00877396 Phase 4
19 A Multi-Center, Open-Label Study Evaluating Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Enzyme Replacement Therapy Completed NCT00607386 Phase 4
20 A Randomized Controlled Trial of Live Attenuated Vaccine Versus Trivalent Inactivated Vaccine in Hutterite Children Completed NCT01653015 Phase 4
21 Comparison of Postoperative Infection and Graft Uptake Rate Using Single Dose of Intravenous Co-amoxiclav Versus no Antibiotic in Children Undergoing Myringoplasty Completed NCT03700814 Phase 4 Co-amoxiclav
22 TEAM (Trial on Efficacy and Quality of Life Among Asthmatic Patient With Montelukast) Completed NCT03096327 Phase 4 Montelukast;Placebo
23 Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. A Prospective, Randomised, Clinical Trial. Completed NCT01694108 Phase 4
24 Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric Completed NCT02617771 Phase 4 Vitamin D3
25 A Phase IV, Single Group Study to Evaluate the Immunogenicity and Safety in UK Laboratory Workers of a Licensed Hib and Meningococcal C Conjugate Combined Vaccine (Menitorix) Completed NCT00503165 Phase 4
26 In Vivo Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria: an Open-randomised, Non-inferiority Clinical Trial in South Kivu, DR Congo Completed NCT02741024 Phase 4 Amodiaquine-Artesunate (ASAQ);Artemether-Lumefantrine (AL)
27 Effect of Antimicrobial Treatment of Acute Otitis Media on the Intestinal Microbiome in Children: A Randomized Controlled Trial Recruiting NCT02935374 Phase 4 Amoxicillin;Amoxicillin-Potassium Clavulanate;Macrolide
28 Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Controlled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive and Mucosal Infections. Active, not recruiting NCT01735084 Phase 4
29 Efficacy and Cost Analysis of Steroid Spray in Treatment of Otitis Media With Effusion (OME) Compared to That of Antibiotic, Antihistaminic, and Nasal Decongestant Not yet recruiting NCT03590912 Phase 4 Fluticasone Nasal;Anti Histamine plus Nasal decongestents;Steroid Drug
30 N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media Not yet recruiting NCT00956748 Phase 4 Ciprodex;Ciprodex and 2% NAC
31 Does the Use of Topical Otic Drops at the Time of Tympanostomy Tube Placement Improve Outcomes When no Middle Ear Effusion is Present at the Time of Surgery Not yet recruiting NCT03655665 Phase 4 Ofloxacin otic solution
32 Role of Montelukast in Asthma and Allergic Rhinitis Patients Not yet recruiting NCT03380975 Phase 4 Montelukast 10mg
33 Effect of Vaxoral® (OM-85) on Frequency of Respiratory Tract Infections and Size of Adenoid Tissue in Preschool Children With Adenoid Hypertrophy Not yet recruiting NCT03243565 Phase 4
34 Otiprio Versus Ciprodex to Reduce Tympanostomy Tube Failure Withdrawn NCT03347461 Phase 4 Otiprio;Ciprodex
35 A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux Withdrawn NCT01308502 Phase 4
36 A Randomized Control Study of the Outcomes of Mastoidotympanoplasty Versus Tympanoplasty in Quiescent Tubotympanic Otitis Media Unknown status NCT00271778 Phase 3
37 PneuMum: A Randomised Controlled Trial of Pneumococcal Polysaccharide Vaccination for Aboriginal and Torres Strait Islander Mothers to Protect Their Babies From Ear Disease Unknown status NCT00310349 Phase 3
38 A Study of Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines to Inform Policy Regarding Pneumococcal Vaccination of Papua New Guinean Children Unknown status NCT01619462 Phase 3
39 Reducing Disease Burden and Health Inequalities Arising From Chronic Dental Disease Among Indigenous Children: an Early Childhood Caries Intervention Unknown status NCT02151916 Phase 3
40 A Clinical Study of the Acclarent Tympanostomy Tube Delivery System for the Treatment of Patients Requiring Tympanostomy Tube Insertion for Otitis Media Completed NCT01202578 Phase 2, Phase 3
41 An Open-Label, Safety and Efficacy Study of Cefdinir Oral Suspension, 25 mg/kg Once Daily, in Pediatric Subjects With Acute Otitis Media Completed NCT00645203 Phase 2, Phase 3 cefdinir
42 Safety and Efficacy of EXE844 Otic Suspension in the Treatment of Otitis Media at Time of Tympanostomy Tube Insertion Completed NCT02436304 Phase 3 EXE844 Sterile Otic Suspension, 0.3%
43 Safety and Efficacy of EXE844 Otic Suspension in the Treatment of Otitis Media at Time of Tympanostomy Tube Insertion Completed NCT02432105 Phase 3 EXE844 Sterile Otic Suspension, 0.3%
44 Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children Completed NCT02541760 Phase 3 Monteleukast;Mometasone
45 Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children Completed NCT01044030 Phase 3 Xylitol syrup;Placebo
46 A Randomized, Multicenter, Comparative Study To Assess Tolerability Of A Single Oral 60 Mg/Kg Dose Of Zmax (Pediatric Concentration) Vs. Zmax (Adult Concentration) In Pediatric Patients With Acute Otitis Media Completed NCT00360100 Phase 3 Zmax
47 Evaluation of the Safety, Efficacy, Pharmacokinetics, and Acceptability of HMR3647 20 mg/kg qd for 5 Days With Acute Otitis Media (AOM) in Children (Multicenter, Open Label, Non Comparative Study) Completed NCT00638534 Phase 3 Telithromycin (HMR3647)
48 Oral Amoxicillin-clavulanate in Treating Acute Otitis Media in Children: Randomized Double-blind Placebo-controlled Study Including Daily Monitoring With Tympanometry Completed NCT01244581 Phase 3 Amoxicillin-clavulanate;Placebo
49 An 8-Week, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes Completed NCT02600559 Phase 3 OTO-201 (ciprofloxacin)
50 Acute Otitis Media: Adjuvant Therapy to Improve Outcome Completed NCT00000363 Phase 3 Antihistamine;Corticosteroid

Search NIH Clinical Center for Otitis Media

Inferred drug relations via UMLS 72 / NDF-RT 51 :


acetyl sulfisoxazole
Antipyrine
Benzocaine
BENZOCAINE PWDR
Cefpodoxime
CEFTIBUTEN DIHYDRATE
Cephalexin
Ciprofloxacin
Clarithromycin
Clavulanic acid
Clindamycin
Sulfamethoxazole
Sulfisoxazole
Sulfisoxazole Diolamine

Cochrane evidence based reviews: otitis media

Genetic Tests for Otitis Media

Genetic tests related to Otitis Media:

# Genetic test Affiliating Genes
1 Otitis Media 29
2 Otitis Media, Susceptibility to 29 A2ML1

Anatomical Context for Otitis Media

MalaCards organs/tissues related to Otitis Media:

41
Bone, Testes, Brain, Colon, Tonsil, Neutrophil, Breast

Publications for Otitis Media

Articles related to Otitis Media:

(show top 50) (show all 19897)
# Title Authors PMID Year
1
Genetic and Environmental Determinants of Otitis Media in an Indigenous Filipino Population. 38 8 71
27484237 2016
2
Rare A2ML1 variants confer susceptibility to otitis media. 38 8
26121085 2015
3
Eya4-deficient mice are a model for heritable otitis media. 38 8
18219393 2008
4
Chronic and recurrent otitis media: a genome scan for susceptibility loci. 38 8
15514890 2004
5
The heritability of otitis media: a twin and triplet study. 38 8
10591333 1999
6
Susceptibility to otitis media: strong evidence that genetics plays a role. 38 8
10591340 1999
7
Familial predisposition for otitis media in Apache Indians at Canyon Day, Arizona. 38 8
3569876 1987
8
Mucin gene polymorphisms in otitis media patients. 9 38
19718741 2010
9
[Evaluation of percentage of lymphocytes B with expression of co-receptors CD 40, CD22 and CD72 in hypertrophied adenoid at children with otitis media with effusion]. 9 38
20198985 2009
10
Glucocorticoids inhibit nontypeable Haemophilus influenzae-induced MUC5AC mucin expression via MAPK phosphatase-1-dependent inhibition of p38 MAPK. 9 38
18957283 2008
11
Toll-like receptors 2 and 4 and their mutations in patients with otitis media and middle ear effusion. 9 38
19434266 2008
12
Antibodies to pneumococcal surface protein A families 1 and 2 in serum and saliva of children and the risk of pneumococcal acute otitis media. 9 38
18008233 2007
13
Association of CD14 promoter polymorphism with otitis media and pneumococcal vaccine responses. 9 38
16893989 2006
14
Functional polymorphisms in the mannan-binding lectin 2 gene: effect on MBL levels and otitis media. 9 38
16750996 2006
15
[The measuring of ECP and IgE in middle ear effusion of patients with otitis media of effusion]. 9 38
16883790 2006
16
Total serum IgE and IgE antibodies specific to house dust mite found in two aged-matched cohorts of children with and without otitis media with effusion. 9 38
16620332 2006
17
Up-regulation of MUC5AC and MUC5B mucin genes in nasopharyngeal respiratory mucosa and selective up-regulation of MUC5B in middle ear in pediatric otitis media with effusion. 9 38
16540890 2006
18
Role of mannose-binding lectin (MBL2) genotyping in predicting the risk of recurrent otitis media (rOM). 9 38
16893079 2006
19
Childhood levels of immunoglobulins and mannan-binding lectin in relation to infections and allergy. 9 38
15882439 2005
20
Immunological status in the aetiology of recurrent otitis media with effusion: serum immunoglobulin levels, functional mannose-binding lectin and Fc receptor polymorphisms for IgG. 9 38
15742161 2005
21
Immunological parameters in girls with Turner syndrome. 9 38
15563731 2004
22
IL-5 and eotaxin levels in middle ear effusion and blood from asthmatics with otitis media with effusion. 9 38
12737295 2003
23
Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase. 9 38
11867630 2002
24
Human lactoferrin proteolytic activity: analysis of the cleaved region in the IgA protease of Haemophilus influenzae. 9 38
11163480 2000
25
Increased expression of major basic protein (MBP) and interleukin-5(IL-5) in middle ear biopsy specimens from atopic patients with persistent otitis media with effusion. 9 38
11077335 2000
26
[Immunology in the medical practice. XXVII. Mannose-binding lectin, an important link for nonspecific or hereditary immune reaction]. 9 38
10897301 2000
27
Eosinophils and neutrophils in biopsies from the middle ear of atopic children with otitis media with effusion. 9 38
10669113 1999
28
The influence of karyotype on the auricle, otitis media and hearing in Turner syndrome. 9 38
10575123 1999
29
Evidence of possible localized specific immunoglobulin E production in middle ear fluid as demonstrated by ELISA testing. 9 38
10471862 1999
30
Microbial factors leading to recurrent upper respiratory tract infections. 9 38
9727652 1998
31
Eosinophil cationic protein in mucosal biopsies from patients with allergy and otitis media with effusion. 9 38
9230321 1997
32
Association of otitis media with effusion and allergy as demonstrated by intradermal skin testing and eosinophil cationic protein levels in both middle ear effusions and mucosal biopsies. 9 38
8822719 1996
33
Levels of eosinophil cationic protein and myeloperoxidase from chronic middle ear effusion in patients with allergy and/or acute infection. 9 38
8643262 1996
34
Mannan-binding protein--levels in plasma and upper-airways secretions and frequency of genotypes in children with recurrence of otitis media. 9 38
8403525 1993
35
The presence of eosinophil cationic protein in middle ear effusion. 9 38
8516010 1993
36
Correlation between serum immunoglobulin A concentrations and allergic manifestations in infants. 9 38
1625088 1992
37
Sulbactam/ampicillin in the treatment of otitis and sinusitis. 9 38
2060691 1991
38
The role of bacterial adherence in otitis media with effusion. 9 38
2206498 1990
39
Prospective study about the incidence of B lactamase producing bacteriae in otitis media in the population of the emergency room of the University Pediatric Hospital. 9 38
2375816 1990
40
Middle ear abnormalities at age 5 years in relation with early onset otitis media and number of episodes, in the Inuit population of Nunavik, Quebec, Canada. 38
30924406 2019
41
Why do infants pull their ears? 38
30898404 2019
42
Expression of C-type lectin receptor mRNA in otitis media with effusion and chronic otitis media with and without cholesteatoma. 38
30609964 2019
43
A case of otitis externa caused by Schizophyllum commune: An approach to antimicrobial stewardship using Gram staining of otorrhea in a medical clinic. 38
30905630 2019
44
Role of rapid diagnostics for viral respiratory infections in antibiotic prescribing decision in the emergency department. 38
31250772 2019
45
Does access to saltwater swimming pools reduce ear pathology and hearing loss in school children of remote arid zone aboriginal communities? A prospective 3-year cohort study. 38
31095860 2019
46
Imaging of temporal bone inflammations in children: a pictorial review. 38
31321462 2019
47
Differentiation Between Eosinophilic Otitis Media and Otitis Media Associated With Eosinophilic Granulomatosis With Polyangiitis. 38
31290803 2019
48
Translating Recent Microbiome Insights in Otitis Media into Probiotic Strategies. 38
31270125 2019
49
Genetic characteristics and antibiotic resistance of Haemophilus influenzae isolates from pediatric patients with acute otitis media after introduction of 13-valent pneumococcal conjugate vaccine in Japan. 38
30987951 2019
50
Epigallocatechin-3-gallate (EGCG) exert therapeutic effect on acute inflammatory otitis media in rats. 38
31176023 2019

Variations for Otitis Media

ClinVar genetic disease variations for Otitis Media:

6 (show all 17)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 A2ML1 NM_144670.6(A2ML1): c.2478_2485dup (p.Ser829fs) duplication Pathogenic,risk factor rs863224951 12:9004820-9004827 12:8852224-8852231
2 A2ML1 NM_144670.6(A2ML1): c.4061+1G> C single nucleotide variant Pathogenic 12:9020954-9020954 12:8868358-8868358
3 A2ML1 NM_144670.6(A2ML1): c.10C> T (p.Gln4Ter) single nucleotide variant Likely pathogenic 12:8975257-8975257 12:8822661-8822661
4 A2ML1 NM_144670.6(A2ML1): c.2197T> C (p.Phe733Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs117213221 12:9002833-9002833 12:8850237-8850237
5 A2ML1 NM_144670.6(A2ML1): c.2713-8C> A single nucleotide variant Conflicting interpretations of pathogenicity rs184386564 12:9007368-9007368 12:8854772-8854772
6 A2ML1 NM_144670.6(A2ML1): c.2677C> T (p.Arg893Ter) single nucleotide variant Uncertain significance rs199651558 12:9006810-9006810 12:8854214-8854214
7 A2ML1 NM_144670.6(A2ML1): c.971-8C> T single nucleotide variant Uncertain significance 12:8991701-8991701 12:8839105-8839105
8 A2ML1 NM_144670.6(A2ML1): c.1308A> C (p.Gln436His) single nucleotide variant Uncertain significance 12:8995789-8995789 12:8843193-8843193
9 A2ML1 NM_144670.6(A2ML1): c.2012T> C (p.Leu671Pro) single nucleotide variant Uncertain significance 12:9001494-9001494 12:8848898-8848898
10 A2ML1 NM_144670.6(A2ML1): c.2329G> A (p.Gly777Arg) single nucleotide variant Uncertain significance 12:9004474-9004474 12:8851878-8851878
11 A2ML1 NM_144670.6(A2ML1): c.164C> T (p.Thr55Ile) single nucleotide variant Uncertain significance 12:8975879-8975879 12:8823283-8823283
12 A2ML1 NM_144670.6(A2ML1): c.1683G> C (p.Gln561His) single nucleotide variant Uncertain significance 12:8998818-8998818 12:8846222-8846222
13 A2ML1 NM_144670.6(A2ML1): c.2189G> A (p.Arg730His) single nucleotide variant Uncertain significance 12:9002825-9002825 12:8850229-8850229
14 A2ML1 NM_144670.6(A2ML1): c.2228C> T (p.Pro743Leu) single nucleotide variant Uncertain significance 12:9002864-9002864 12:8850268-8850268
15 A2ML1 NM_144670.6(A2ML1): c.2545G> T (p.Asp849Tyr) single nucleotide variant Uncertain significance 12:9004887-9004887 12:8852291-8852291
16 A2ML1 NM_144670.6(A2ML1): c.2971G> C (p.Ala991Pro) single nucleotide variant Uncertain significance 12:9009882-9009882 12:8857286-8857286
17 A2ML1 NM_144670.6(A2ML1): c.3491C> T (p.Ala1164Val) single nucleotide variant Uncertain significance 12:9013882-9013882 12:8861286-8861286

Expression for Otitis Media

LifeMap Discovery
Genes differentially expressed in tissues of Otitis Media patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 PNLIPRP3 pancreatic lipase-related protein 3 Blood - 6.47 0.003
2 FAM20A family with sequence similarity 20, member A Blood + 3.09 0.015
Search GEO for disease gene expression data for Otitis Media.

Pathways for Otitis Media

Pathways related to Otitis Media according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 TNF TLR4 TLR2 RNASE3 MUC5B MUC5AC
2
Show member pathways
13.43 TNF TLR4 TLR2 IL6 IL1B CXCL8
3
Show member pathways
13.36 TNF IL6 IL1B IGHE CXCL8 CD40LG
4
Show member pathways
13.08 TNF TLR4 TLR2 SFTPA2 MBL2 IL6
5
Show member pathways
12.97 TNF TLR4 TLR2 IL6 IL1B CXCL8
6
Show member pathways
12.91 TNF RNASE3 IL6 IL1B CXCL8 CD40LG
7
Show member pathways
12.77 TNF TLR4 IL6 IL1B CXCL8
8
Show member pathways
12.74 TNF TLR4 TLR2 IL6 IL1B CD40LG
9
Show member pathways
12.63 TNF TLR4 TLR2 IL1B CD40LG
10
Show member pathways
12.62 TNF TLR4 TLR2 IL6 IL1B
11 12.59 TNF TLR2 IL1B CD79A CD40LG
12
Show member pathways
12.55 TNF IL6 IL1B CD40LG
13
Show member pathways
12.35 TNF TLR4 IL6 IL1B CXCL8
14
Show member pathways
12.31 TNF TLR4 TLR2 IL6 CXCL8
15
Show member pathways
12.3 TNF TLR4 TLR2 IL1B CD40LG
16 12.26 TNF TLR4 TLR2 IL6 IL1B
17
Show member pathways
12.26 TNF TLR2 MUC5B MUC5AC IL6 IL1B
18 12.21 TNF TLR4 TLR2 IL6
19 12.2 TNF IL6 IL1B CXCL8
20
Show member pathways
12.19 TNF TLR2 MUC5B MUC5AC IL6 IL1B
21 12.18 TLR4 TLR2 SFTPA2 SFTPA1 MBL2
22
Show member pathways
12.09 TNF TLR4 TLR2 IL6 IL1B
23
Show member pathways
12.08 TNF TLR4 TLR2 SFTPA1 IL6 IL1B
24
Show member pathways
12.07 TNF TLR4 TLR2 IL6 IL1B
25 12.03 TNF TLR4 IL6 IL1B CXCL8
26 12.01 TNF IL6 IL1B IGHE CXCL8 CCL11
27 11.95 TNF IL6 IL1B CXCL8
28 11.94 TNF TLR4 TLR2 IL6 IL1B CXCL8
29 11.93 TNF TLR4 IL1B CXCL8 CD40LG
30 11.88 TNF IL6 IL1B
31 11.88 TNF TLR4 TLR2 IL6 IL1B CXCL8
32
Show member pathways
11.86 TLR4 IL6 CXCL8
33 11.86 TLR4 IL6 IL1B CXCL8
34 11.77 TNF IL6 IL1B CCL11
35
Show member pathways
11.76 TNF CXCL8 CD40LG
36 11.75 TNF IL6 IL1B
37
Show member pathways
11.69 TNF IL6 IL1B CXCL8 CD40LG
38 11.67 IGHE CD40LG CCL11
39 11.59 TNF IL6 IL1B CXCL8
40 11.59 TNF TLR4 TLR2 IL6 IL1B CXCL8
41 11.58 TNF TLR4 SFTPA2 SFTPA1 IL6 IL1B
42 11.57 TNF TLR4 TLR2 IL1B
43 11.54 IL6 CXCL8 CCL11
44 11.51 TNF IL6 IL1B
45 11.41 TNF IL6 IL1B
46 11.38 TNF TLR4 IL6 IL1B
47 11.35 TNF IL6 IL1B
48 11.33 TNF IL6 IL1B
49 11.3 TNF IL6 IL1B
50 11.22 TNF IL6 IL1B CXCL8 CD40LG CCL11

GO Terms for Otitis Media

Cellular components related to Otitis Media according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TNF SFTPA2 SFTPA1 RNASE3 MUC5B MUC5AC
2 external side of plasma membrane GO:0009897 9.65 TNF TLR4 IGHE CD79A CD40LG
3 collagen trimer GO:0005581 9.54 SFTPA2 SFTPA1 MBL2
4 extracellular space GO:0005615 9.44 TNF SFTPA2 SFTPA1 RNASE3 MUC5B MUC5AC
5 multivesicular body GO:0005771 9.33 SFTPA2 SFTPA1 CD79A
6 lamellar body GO:0042599 9.32 SFTPA2 SFTPA1

Biological processes related to Otitis Media according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.99 TNF TLR4 RNASE3 MBL2 IGHE
2 cytokine-mediated signaling pathway GO:0019221 9.99 TNF IL6 IL1B IGHE CXCL8 CCL11
3 cellular response to lipopolysaccharide GO:0071222 9.93 TNF TLR4 IL6 IL1B CXCL8
4 defense response to Gram-negative bacterium GO:0050829 9.87 TLR4 RNASE3 IL6
5 positive regulation of JNK cascade GO:0046330 9.86 TNF TLR4 IL1B
6 neutrophil chemotaxis GO:0030593 9.86 IL1B CXCL8 CCL11
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.85 TNF TLR4 CCL11
8 positive regulation of inflammatory response GO:0050729 9.85 TNF TLR4 TLR2
9 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 TNF TLR4 TLR2 IL1B
10 defense response to Gram-positive bacterium GO:0050830 9.83 TNF TLR2 RNASE3 MBL2 IL6
11 positive regulation of T cell proliferation GO:0042102 9.82 IL6 IL1B CD40LG
12 positive regulation of interferon-gamma production GO:0032729 9.8 TNF TLR4 IL1B
13 toll-like receptor signaling pathway GO:0002224 9.8 TLR4 TLR2 SFTPA2 SFTPA1
14 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 TNF TLR4 TLR2 IL6 IL1B CD40LG
15 positive regulation of nitric oxide biosynthetic process GO:0045429 9.79 TNF TLR4 IL1B
16 lipopolysaccharide-mediated signaling pathway GO:0031663 9.78 TNF TLR4 TLR2 IL1B
17 inflammatory response GO:0006954 9.76 TNF TLR4 TLR2 IL6 IL1B CXCL8
18 positive regulation of interleukin-12 production GO:0032735 9.75 TLR4 TLR2 CD40LG
19 negative regulation of neurogenesis GO:0050768 9.74 TNF IL6 IL1B
20 positive regulation of interleukin-10 production GO:0032733 9.73 TLR4 TLR2 CD40LG
21 positive regulation of glial cell proliferation GO:0060252 9.72 TNF IL6 IL1B
22 positive regulation of interleukin-8 production GO:0032757 9.71 TNF TLR4 TLR2 IL1B
23 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.7 TLR4 TLR2
24 response to molecule of bacterial origin GO:0002237 9.69 TLR2 CXCL8
25 I-kappaB phosphorylation GO:0007252 9.69 TLR4 TLR2
26 surfactant homeostasis GO:0043129 9.68 SFTPA2 SFTPA1
27 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.67 TNF TLR4
28 cellular response to lipoteichoic acid GO:0071223 9.67 TLR4 TLR2
29 positive regulation of chemokine production GO:0032722 9.67 TNF TLR4 TLR2 IL6
30 opsonization GO:0008228 9.66 SFTPA1 MBL2
31 negative regulation of lipid storage GO:0010888 9.66 TNF IL6
32 response to glucocorticoid GO:0051384 9.65 TNF IL6
33 positive regulation of chemokine biosynthetic process GO:0045080 9.65 TNF IL1B
34 positive regulation of interleukin-6 production GO:0032755 9.65 TNF TLR4 TLR2 IL6 IL1B
35 regulation of establishment of endothelial barrier GO:1903140 9.64 TNF IL1B
36 regulation of immunoglobulin secretion GO:0051023 9.63 TNF CD40LG
37 positive regulation of fever generation GO:0031622 9.63 TNF IL1B
38 positive regulation of neuroinflammatory response GO:0150078 9.63 TNF IL6 IL1B
39 sequestering of triglyceride GO:0030730 9.61 TNF IL1B
40 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.6 TNF IL1B
41 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 9.58 TLR4 TLR2
42 regulation of cytokine secretion GO:0050707 9.4 TLR2
43 positive regulation of phagocytosis GO:0050766 9.35 TNF SFTPA2 SFTPA1 MBL2 IL1B
44 chronic inflammatory response to antigenic stimulus GO:0002439 9.3 TNF
45 immune response GO:0006955 9.28 TNF TLR4 TLR2 IL6 IL1B IGHE
46 innate immune response GO:0045087 10.09 TLR4 TLR2 RNASE3 MBL2 IGHE
47 positive regulation of gene expression GO:0010628 10.04 TNF TLR4 TLR2 IL6 IL1B

Molecular functions related to Otitis Media according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 TNF IL6 IL1B CXCL8 CD40LG CCL11
2 lipopolysaccharide receptor activity GO:0001875 9.16 TLR4 TLR2
3 lipopolysaccharide binding GO:0001530 9.02 TLR4 TLR2 SFTPA2 SFTPA1 RNASE3

Sources for Otitis Media

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....